Leila Arabi

Dr. Leila Arabi

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2023 in Drug Delivery and Translational Research
Verified
Journal Article
Closed access
PDF file
SSSedigheh Shahvali
Sedigheh Shahvali
NRNiloufar Rahiman
Niloufar Rahiman
MJMahmoud Reza Jaafari
Mahmoud Reza Jaafari
LALeila Arabi
Leila Arabi

15 June 2024 in Journal of Controlled Release
Verified
Journal Article
Closed access
SSSetareh Soroudi
Setareh Soroudi
MJMahmoud Reza Jaafari
Mahmoud Reza Jaafari
LALeila Arabi
Leila Arabi

20 March 2025 in Journal of Controlled Release
Verified
Journal Article
Closed access
SMSeyedeh Ghazal Moosavi
Seyedeh Ghazal Moosavi
NRNiloufar Rahiman
Niloufar Rahiman
MJMahmoud Reza Jaafari
Mahmoud Reza Jaafari
LALeila Arabi
Leila Arabi

1 December 2022 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
MGMahsa Ghodousi
Mahsa Ghodousi
HKHedyieh Karbasforooshan
Hedyieh Karbasforooshan
LALeila Arabi
Leila Arabi
SESepideh Elyasi
Sepideh Elyasi

3 August 2025 in Drug Delivery
Verified
Journal Article
Open access
VMVahideh Mohammadzadeh
Vahideh Mohammadzadeh
LALeila Arabi
Leila Arabi
SHSeyedeh Maryam Hosseinikhah
Seyedeh Maryam Hosseinikhah
MMMohammad Mashreghi
Mohammad Mashreghi
FKFatemeh Kalalinia
Fatemeh Kalalinia
MJMahmoud Reza Jaafari
Mahmoud Reza Jaafari
The therapeutic efficacy of nanoparticle (NP)-encapsulated cytotoxic drugs has remained limited by poor penetration into solid tumors. To address this challenge, we developed a novel strategy using minoxidil-loaded nanoliposomes (Lip-MXD) to induce tumor vasodilation and enhance the delivery of PEGylated liposomal doxorubicin (PLD). We developed a remote loading method utilizing a calcium acetate gradient to encapsulate MXD into liposomes, achieving a high MXD encapsulation efficiency (87%). The resulting Lip-MXD formulation displayed an average particle size of 111 nm, a polydispersity index of 0.05, and a zeta potential of -15.7 mV. Pretreatment with Lip-MXD demonstrated multifunctional effects. It significantly downregulated CLDN-1 expression, improving NP penetration into advanced, fibrotic tumors. The stability of interaction between CLDN-1 and MXD was confirmed by molecular dynamics (MD) simulation. Immunohistochemistry and gene expression analyses in mouse models of colorectal (CRC) and pancreatic (PCa) cancers revealed that Lip-MXD administration significantly reduced the number of tumor-associated stromal cells. Furthermore, Lip-MXD mitigated tumor hypoxia and substantially enhanced PLD permeability within the dense microenvironment of desmoplastic tumors through its vasodilatory effects. A single dose of PLD following Lip-MXD pretreatment exhibited significant antitumor activity, resulting in a prolonged survival rate of 60% in the Lip-MXD+PLD-treated group in CRC models. In nude mice bearing PCa, the Lip-MXD+PLD-treated group achieved a significant reduction in tumor volume compared to the PLD group over a 14-day evaluation period. This MXD liposomal formulation offers a promising method to overcome tumor penetration, enhance NP delivery and improve therapeutic outcomes in CRC and PCa cancers, meriting further investigation.

12 June 2024 in International Immunopharmacology
Verified
Journal Article
Closed access
RKRahimeh Khoshkhabar
Rahimeh Khoshkhabar
MYMona Yazdani
Mona Yazdani
SASeyedeh Hoda Hoda Alavizadeh
Seyedeh Hoda Hoda Alavizadeh
ZSZahra Saberi
Zahra Saberi
LALeila Arabi
Leila Arabi
MJMahmoud Reza Jaafari
Mahmoud Reza Jaafari